A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA

Registry ID

WO29637

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Start date

2018-06-13

Last update

2015-04-09

Conditions

• RENAL CELL CARCINOMA METASTATIC

Related clinical trials

• A PHASE 2, SINGLE-ARM, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB PLUS LENVATINIB IN PARTICIPANTS WITH FIRST LINE ADVANCED/METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC) (KEYNOTE-B61)
• A PHASE III RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH AXITINIB VERSUS SUNITINIB MONOTHERAPY AS A FIRST-LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (MRCC) (KEYNOTE-426)
• A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA) VERSUS SUNITINIB (SUTENT) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
• A MULTI-CENTER, OPEN LABEL, RANDOMIZED PHASE 2 STUDY OF AGS-16C3F VS AXITINIB IN METASTATIC RENAL CELL CARCINOMA

View on source registry